Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, presents the updated results of the ANDROMEDA trial (NCT03201965), a Phase III randomized global international multi-center clinical trial that evaluated the efficacy of daratumumab plus bortezomib, cyclophosphamide, and dexamethasone, (CyBorD or VCD) compared to VCD alone in treating newly diagnosed light chain (AL) amyloidosis. Dr Sanchorawala highlights that the trial demonstrated significant benefits with the addition of daratumumab to the VCD treatment regimen, with improved hematologic complete response (CHR), major organ deterioration progression-free survival (PFS), and overall survival (OS), as well as a complete cardiac response in 40% of patients. She notes that this is set to become the new standard of care for patients with AL amyloidosis. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
